Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer.
Eur J Nucl Med Mol Imaging
; 46(1): 8-10, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30310953
[Consensus of Chinese experts on the application of molecular imaging targeting prostate specific membrane antigen in prostate cancer patients].
Prostate-specific membrane antigen radioligand therapy of prostate cancer.
Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
Ga Prostate-specific Membrane Antigen PET/CT for Primary Diagnosis of Prostate Cancer: Complementary or Alternative to Multiparametric MR Imaging.
Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.
What's in a Label? Radioimmunotherapy for metastatic prostate cancer.
Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
Prostate-specific membrane antigen-directed nanoparticle targeting for extreme nearfield ablation of prostate cancer cells.
Detection and quantitation of glutamate carboxypeptidase II in human blood.
Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.